![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
19 views
June 10, 2022
Comments 0
Login to view comments.
Click here to Login
Lung